| Market Capitalization (Millions $) |
77 |
| Shares
Outstanding (Millions) |
114 |
| Employees |
315 |
| Revenues (TTM) (Millions $) |
146 |
| Net Income (TTM) (Millions $) |
-140 |
| Cash Flow (TTM) (Millions $) |
-28 |
| Capital Exp. (TTM) (Millions $) |
0 |
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc. is a biopharmaceutical company that is primarily focused on the development and commercialization of novel therapies for the treatment of cancer and other related diseases. The company's core technology platform is based on the identification and targeting of nuclear transport mechanisms, which are essential for the survival and growth of cancer cells.
The company was founded in 2008 and is headquartered in Newton, Massachusetts. It has operations in Europe and Asia, with strategic partners and collaborators spanning across North America, South America, Europe, Asia, and Africa.
Karyopharm's lead product candidate is XPOVIO (selinexor), which was approved by the US FDA in 2019 for the treatment of relapsed or refractory multiple myeloma. Selinexor is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that targets the nuclear export protein XPO1 (exportin 1), causing a buildup of tumor suppressor proteins in the nucleus of cancer cells, leading to cell death.
Apart from XPOVIO, Karyopharm has a pipeline of drug candidates in various stages of development, targeting multiple cancer indications, including acute myeloid leukemia, liposarcoma, diffuse large B-cell lymphoma, and others. The company is also exploring the potential of its technology platform for the treatment of neurodegenerative diseases, inflammation, and viral infections.
Karyopharm has established collaborations with leading academic institutions, such as the National Cancer Institute, Dana-Farber Cancer Institute, and the Memorial Sloan Kettering Cancer Center, to support the preclinical and clinical development of its drug candidates. The company has also partnered with leading pharma companies, such as Biogen, Antengene, and Ono Pharmaceutical, to expand its market reach and accelerate the commercialization of its products.
In summary, Karyopharm Therapeutics Inc. is a biopharmaceutical company that is committed to developing and commercializing innovative therapies for cancer and other diseases, based on its nuclear transport technology platform. With a growing pipeline of drug candidates, a strong scientific and clinical team, and strategic collaborations with leading institutions and pharma companies, Karyopharm is well-positioned to realize its vision of transforming cancer care and improving patient outcomes.
Company Address: 85 Wells Avenue, 2nd Floor Newton 2459 MA
Company Phone Number: 658-0600 Stock Exchange / Ticker: NASDAQ KPTI
| KPTI is expected to report next financial results on February 16, 2024. |
|
|
